Impact News +++ Synbiotic: Tochter muss zum Amtsgericht (4investors) +++ SYNBIOTIC Aktie -4,25%

INOVIO Aktie

>INOVIO Aktienkurs

0.975 EUR +0.2% (TradegateBSX)

Ask: 1.007 EUR / 2975 Stück

Bid: 0.958 EUR / 3128 Stück

Tagesumsatz: 3500 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INOVIO Aktie über LYNX handeln

Intraday

1 Jahr

>INOVIO Performance

1 Woche: +0,8%

1 Monat: -9,0%

3 Monate: -32,7%

6 Monate: -51,4%

1 Jahr: -45,0%

laufendes Jahr: -35,0%

>INOVIO Aktie

Name:

INOVIO PHARMACEUTICAL INC

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45773H4092 / A400EJ

Symbol/ Ticker:

GBM (Frankfurt) / INO (NASDAQ)

Kürzel:

FRA:GBM, ETR:GBM, GBM:GR, NASDAQ:INO

Index:

Webseite:

https://inovio.com/

Profil:

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing DNA medicines for treating and protecting against HPV-related diseases, cancer, and infectious diseases. The company employs proprietar..
>Volltext..

Marktkapitalisierung:

79.68 Mio. EUR

Unternehmenswert:

54.5 Mio. EUR

Umsatz:

EBITDA:

-70.44 Mio. EUR

Nettogewinn:

-74.11 Mio. EUR

Gewinn je Aktie:

-1.49 EUR

Schulden:

7.59 Mio. EUR

Liquide Mittel:

22.92 Mio. EUR

Operativer Cashflow:

-72.72 Mio. EUR

Bargeldquote:

0.99

Umsatzwachstum:

-100%

Gewinnwachstum:

17.57%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

INOVIO

Letzte Datenerhebung:

19.06.26

>INOVIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 82.27 Mio. St.

Frei handelbar: 99.53%

Leerverk. Aktien: 19.77%

Rückkaufquote: -58.19%

Mitarbeiter: 112

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 437.61%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 12.42

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -123.95%

Eigenkaprendite: -296.36%

>INOVIO Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika

>INOVIO Chart & Kurs - NASDAQ

>INOVIO News

04.06.26 - 22:39	Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm (PR Newswire)
	NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,......

28.05.26 - 14:09	INOVIO to Participate in Upcoming Scientific and Investor Conferences (PR Newswire)
	PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in......

22.05.26 - 18:39	Inovio gains on late-stage trial win for DNA shot (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.05.26 - 22:06	Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO′s Partner in China (PR Newswire)
	Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by......

19.05.26 - 14:12	Inovio übertrifft Gewinnprognose für Q1 2026, Aktie fällt dennoch (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.26 - 03:33	Inovio outlines cash runway into Q1 2027 as INO-3107 targets October 30, 2026 PDUFA date (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.26 - 01:45	Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call (Benzinga)
	Importance Rank: 1 read more...

14.05.26 - 00:12	Inovio (INO) Q1 2026 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.26 - 23:36	Earnings Call: Inovio meldet klinische Fortschritte für Q1 2026, Aktie legt um 2,84 % zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.26 - 22:30	Earnings Snapshot: Inovio Pharmaceuticals′ Q1 shows EPS beat; net loss $19.7M improves as R&D costs fall (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.26 - 22:12	Inovio Pharmaceuticals GAAP EPS of -$0.28 beats by $0.07 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.26 - 22:09	INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights (PR Newswire)
	Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial readiness plans continue to advance in......

08.05.26 - 14:09	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
	PLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in......

01.05.26 - 22:09	INOVIO to Report First Quarter Financial Results on May 13, 2026 (PR Newswire)
	PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its first quarter 2026......

07.04.26 - 20:54	INO Deadline Today: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026......

06.04.26 - 09:49	Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO (PR Newswire)
	LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or "the Company") (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

06.04.26 - 08:48	INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or "the Company") (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities......

04.04.26 - 13:21	INO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to......

03.04.26 - 00:21	INO Deadline: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, April 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026......

02.04.26 - 19:12	Kapitalerhöhung mit Verwässerungseffekt: Inovio-Aktie stürzt ab (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Veni, vidi, vici - Ich kam, ich sah, ich siegte. (Caesar über die Schlacht bei Zela gegen Pharnakos II., 47 v. Chr.). - Gajus Julius Caesar

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram